AFP and hepatocellular carcinoma: Furthermore, in a comparative study of HCC occurrence and recurrence in IFN-based and IFN-free therapies, Nagata et al. found that a higher level of post-DAA therapy AFP (> 5.4 ng/mL) was strongly associated with HCC occurrence (p = 0.028) [52].